| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC8776 | CCT 137690 | CCT 137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively). |
|
| DC20875 | CCT 365623 hydrochloride | CCT 365623 (CCT365623) hydrochloride is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
|
| DC20874 | CCT 365623 | CCT 365623(CCT365623, CCT-365623) is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
|
| DC7803 | CCT007093 Featured | CCT007093 is a potent PPM1D (WIP1) inhibitor with IC50 of 8.4 μM. |
|
| DC22464 | CCT-018159 | CCT-01815 is a novel potent inhibitor of Hsp90 ATPase activity with IC50 of 7.1 uM. |
|
| DC12283 | CCT020312 | CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK). |
|
| DC20872 | CCT-031374 | CCT-031374 is a selective β-catenin signaling inhibitor with IC50 of 6.1 uM. |
|
| DC23168 | CCT128930 | CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA. |
|
| DC23163 | CCT129202 Featured | CCT129202 is a potent, selective, ATP-competitive pan-Aurora kinase inhibitor with IC50 of 42, 198 and 227 nM for Aurora A, Aurora B and Aurora C, respectively. |
|
| DC23828 | CCT241161 | CCT241161 is a potent pan-RAF inhibitor with IC50 of 30, 15 and 6 nM for BRAF, V600E-BRAF and C-RAF, also potently inhibits SRC and LCK (IC50=10 and 3 nM, respectively).. |
|
| DC9399 | CCT241533 (hydrochloride) | CCT241533 Hcl is a potent serine/threonine checkpoint kinase (Chk2) inhibitor with IC50 of 3 nM; shows minimal cross-reactivity against a panel of kinases at 1 uM. |
|
| DC9968 | CCT251545 Featured | CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with IC50 value of 5 nM. |
|
| DC9969 | CCT251921 | CCT251921 is a potent, selective, and orally bioavailable small-molecule modulators of the mediator complex-associated kinases CDK8 and CDK19. (IC50 data: CDK8:=2.3 nM; CDK19 = 2.6 nM). |
|
| DC11679 | CCT-367766 Featured | CCT367766 is a potent and the third generation heterobifunctional and PROTAC-based pirin targeting protein degradation probe (PDP), depletes pirin protein expression at low concentration. CCT367766 exhibits a moderate affinity for the CRBN-DDB1 complex with an IC50 value of 490 nM. CCT367766 reveals a good affinity for the recombinant pirin and CRBN with Kd values of 55 nM and 120 nM, respectively. CCT367766 provides a potential chemical tool to study a largely unexplored protein[1]. |
|
| DC10206 | CCX140 | CCX140 is a potent CCR2 antagonist. |
|
| DC12549 | CCX-354 | CCX-354 (GSK-2941266, CCX354-C, CCX354) is a potent, selective, orally-available CCR1 antagonist for the treatment of inflammatory diseases such as rheumatoid arthritis (RA).. |
|
| DC10955 | CD12681 | CD12681 (CD-12681) is a potent, selective RORγ inverse agonist with IC50 of 19 nM, displays no activity against a panel of nuclear receptors (RORα, RARγ, LXRβ, PPARγ and VDR). |
|
| DC20332 | CD38 inhibitor 78c Featured | CD38 inhibitor 78c is a potent, specific, reversible CD38 inhibitor with Ki of 14.5 nM for recombinant human CD38. |
|
| DC20877 | S8 | Cdc25 inhibitor S8 is an anti-fungal small molecule that inhibits cdc25 phosphatase with Ki of 140 uM. |
|
| DC21877 | Cdc7 inhibitor | Cdc7 inhibitor is a potent inhibitor of Cdc7 kinase with pIC50 of 10.01 against CDC7/DBF4 in TR-FRET assays.. |
|
| DC10433 | CDD3505 | CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity. |
|
| DC10432 | CDD3506 | CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity. |
|
| DC22051 | CDD-450 | CDD-450 is an unique inhibitor that selectively blocks p38α activation of proinflammatory kinase MAPK-MK2 while sparing p38α activation of PRAK and ATF2. |
|
| DC11158 | CDK12 inhibitor 2 | CDK12 inhibitor 2 is a potent, selective, non-covalent CDK12 inhibitor with IC50 of 52 nM, displays >192-fold selectivity over CDK2/7/8/9. |
|
| DC11872 | CDK12 inhibitor E9 S-isomer | CDK12 inhibitor E9 S-isomer (E9, CDK12-IN-E9) is a clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. |
|
| DC8596 | Cdk4/6 Inhibitor IV | Cdk4/6 Inhibitor IV is a cell-permeable triaminopyrimidine compound acting as a reversible and ATP-competitive inhibitor of Cdk4/6 (IC50 = 1.5 µM and 5.6 µM for Cdk4/D1 and Cdk6/D1, respectively) |
|
| DC20921 | CDK5 inhibitor 20-223 | CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9. |
|
| DC12528 | CDK9 inhibitor HH1 Featured | CDK9 inhibitor HH1 is a novel potent, highly selective CDK9 inhibitor.. |
|
| DC20335 | CDK9-IN-8 Featured | CDK9-IN-8 is a highly potent, selective CDK9 inhibitor with IC50 of 12 nM, shows good selectivity in CDKs kinase profiling assay against CDK kinases and cell proliferation inhibition. |
|
| DC9478 | CDK9-IN-1 | CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection. |
|
